Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunotherapy: current problems and outlook].

T Tursz1

  • 1Institut Gustave-Roussy, Villejuif.

Bulletin De L'Academie Nationale De Medecine
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

Molecular oncology·2016
Same author

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Breast (Edinburgh, Scotland)·2013
Same author

Chromosome-11q13 gene amplifications in head and neck squamous-cell carcinomas - relation with lymph-node invasion.

International journal of oncology·2011
Same author

Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial.

Current oncology (Toronto, Ont.)·2010
Same author

[Communication around the cancer diagnosis: patient satisfaction and process quality in French Comprehensive Cancer Centers].

Bulletin du cancer·2010
Same author

Need for global action for cancer control.

Annals of oncology : official journal of the European Society for Medical Oncology·2008
Same journal

[Advances and perspectives in vascularized composite allotransplantation preservation].

Bulletin de l'Academie nationale de medecine·2025
Same journal

[COVID-19: Neurological manifestations and complications during the acute phase of the disease].

Bulletin de l'Academie nationale de medecine·2024
Same journal

[Role of psychological factors in post-COVID-19 condition].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[From the origin of Sars-CoV-2 to dangerous virology/biology].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Neurological forms of long COVID in adults: Critical approach].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Post-COVID-19 syndrome].

Bulletin de l'Academie nationale de medecine·2023
See all related articles

Interleukin-2 (IL-2) shows therapeutic effects on metastatic cancers like renal cell carcinoma and melanoma. Future cytokine therapy aims to improve efficacy and reduce toxicities through new discoveries and gene therapy.

Area of Science:

  • Immunology
  • Hematology
  • Biotechnology

Context:

  • Cytokines are key regulators in immune and hematopoietic systems.
  • Genetic engineering enables production of recombinant cytokines for clinical use.
  • Interleukin-2 (IL-2) is the first cytokine demonstrating reproducible therapeutic effects on metastatic solid tumors.

Purpose:

  • To review the therapeutic potential and limitations of Interleukin-2 (IL-2) in cancer treatment.
  • To discuss the role of lymphokine-activated killer (LAK) cells in IL-2 therapy.
  • To explore future directions in cytokine therapy, including new cytokine discovery, understanding toxicities, and gene therapy.

Summary:

  • High-dose IL-2 achieves objective responses in metastatic renal cancers and melanoma, potentially via activated cytotoxic lymphocytes (LAK cells).

Related Experiment Videos

  • Current cytokine therapy is constrained by significant systemic toxicities, including fever, capillary leak syndrome, and organ dysfunction.
  • Future strategies involve identifying novel cytokines, understanding synergistic effects, elucidating toxicity mechanisms, and employing gene therapy for localized cytokine delivery.

    • Impact:

    • IL-2 offers a treatment option for chemo-resistant metastatic cancers, with potential for long-lasting complete responses.
    • Addressing cytokine-induced toxicities is crucial for patient safety and treatment adherence.
    • Advancements in cytokine research and gene therapy promise more effective and safer cancer treatments.